

Owkin and Tribun Health Launch Strategic Partnership to Accelerate Access to AI Solutions for Diagnosis and Pharma Research

September 11th, 2023 – Paris, France – Owkin and Tribun Health announce a strategic partnership to advance the development and global deployment of Artificial Intelligence (AI) Diagnostic and Research solutions for pathology departments and pharma companies. The non-exclusive partnership will see the integration of Owkin's groundbreaking AI diagnostics into Tribun Health's '[Best in KLAS](#)' software platform, *CaloPix*, expanding its portfolio of AI solutions. Moreover, Owkin customers and users will be able to benefit from Tribun Health's fully integrated software platform for research that streamlines pathology data workflows. This research platform, called *EyeDo*, is the heir to the Keen Eye acquisition made in 2022.

"We're thrilled to embark on this partnership with Tribun Health, to help scale global clinical and laboratory access to our ground-breaking AI solutions for biomarker screening, treatment response and patient outcome prediction," says Meriem Sefta, Owkin's Chief Diagnostic Officer. *"We aim to build upon the successful collaboration initiated with the [PortrAlt consortium](#) and together advance our shared mission of supporting healthcare providers in their digital transformation and improving outcomes through precision diagnostics."*

Tribun Health's platform empowers diagnostic laboratories, pharmaceutical, and biotech manufacturers with cutting-edge tools for seamless management, analysis, and sharing of cellular images. *"In our relentless pursuit of supporting labs in their digital journeys, we proudly announce a transformative partnership that will accelerate our business",* said Jean-François Pomerol, CEO at Tribun Health. *"Adding Owkin's advanced algorithms to our third-party solutions portfolio aims to enhance workflows and improve pathologist diagnosis confidence as well as researcher efficiency which could ultimately accelerate personalized treatments for patients."*

Owkin, powered by its extensive international academic research network, and deep experience in multimodal AI and image analysis, addresses clinically challenging and unmet medical needs with user-friendly solutions for digital pathology as part of its fullstack biotech strategy. Owkin's AI diagnostic offering includes a first-in-class, CE-marked diagnostic that optimizes testing for microsatellite instability with routine H&E slides,

[MSIntuit CRC](#) and a risk assessment tool for recurrence in early breast cancer, [RlapsRisk BC](#). Owkin is also developing several other oncology-based diagnostics to enable more accessible and streamlined diagnosis for precision therapies across the globe.

Join **Owkin** [#18] and **Tribun Health** [#F3_03b] at the [European Congress of Pathology](#) taking place at the Convention Centre in Dublin from 10-12 September.

About Owkin

[Owkin](#) is an AI biotechnology company that uses AI to find the right treatment for every patient. We combine the best of human and artificial intelligence to answer the research questions shared by biopharma and academic researchers. By closing the translational gap between complex biology and new treatments, we bring new diagnostics and drugs to patients sooner.

We use AI to identify new treatments, de-risk and accelerate clinical trials and build diagnostic tools. Using federated learning, a pioneering collaborative AI framework, Owkin enables partners to unlock valuable insights from siloed datasets while protecting patient privacy and securing proprietary data.

Owkin was co-founded by Thomas Clozel MD, a former assistant professor in clinical oncology, and Gilles Wainrib, a pioneer in the field of machine learning in biology, in 2016. Owkin has raised over \$300 million and [became a unicorn](#) through investments from leading biopharma companies (Sanofi and BMS) and venture funds (Fidelity, GV and BPI, among others).

About Tribun Health

[Tribun Health](#) leads the field with AI-powered digital pathology solutions, transforming the way pathologists diagnose and treat disease. Our advanced technology, combined with clinical and informatics expertise, delivers unparalleled accuracy, speed, and efficiency in pathology.

Selected for the esteemed French Tech 2030 program, Tribun Health is a two-time [Best in KLAS award winner](#) (2022 & 2023), recognized for exceptional customer satisfaction. We continually innovate in digital pathology and prioritize customer success.

As pioneers in digital pathology workflow solutions, we offer image acquisition, storage, a web-based management system, AI-powered image analysis with deep and machine learning algorithms, remote case sharing with peer review (telepathology), reporting and exceptional professional services and customer care. For more information, [visit Tribun Health's website.](#)

Owkin Contact:

Talia Lliteras

Product Marketing Director Diagnostics

talia.lliteras@owkin.com

Tribun Health Contact:

Lorine Marcoux

Marketing Manager

lmarcoux@tribun.health

+33 1 89 20 38 53